Last quarter (Q ), Arno Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Arno Therapeutics's net income was $-3.85M. See Arno Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 15	Dec 14	Dec 13	Dec 12	Dec 11
Total Revenue	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Operating Expense	$ 11.06M	$ 13.41M	$ 21.49M	$ 16.94M	$ 10.84M	$ 7.65M
Operating Income	$ -11.06M	$ -13.41M	$ -21.49M	$ -16.94M	$ -10.84M	$ -7.65M
Net Non Operating Interest Income Expense	$ -38.32K	$ -20.75K	$ 41.81K	$ -18.55M	$ -6.35M	$ 28.77K
Other Income Expense	$ -2.59M	$ 1.92M	$ 29.22M	$ -4.17M	$ 2.80M	$ -290.93K
Pretax Income	$ -13.70M	$ -11.51M	$ 7.77M	$ -39.66M	$ -14.39M	$ -7.91M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -13.70M	$ -11.51M	$ 7.77M	$ -39.66M	$ -14.39M	$ -7.99M
Basic EPS	$ -0.43	$ -0.56	$ 0.38	$ -5.28	$ -3.20	$ -1.84
Diluted EPS	$ -0.43	$ -0.56	$ 0.31	$ -5.28	$ -3.20	$ -1.84
Basic Average Shares	$ 145.45M	$ 20.41M	$ 20.38M	$ 7.52M	$ 4.54M	$ 4.31M
Diluted Average Shares	$ 145.45M	$ 20.41M	$ 24.81M	$ 7.52M	$ 4.54M	$ 4.31M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 11.06M	$ 13.41M	$ 21.49M	$ 16.94M	$ 10.84M	$ 7.65M
Net Income From Continuing And Discontinued Operation	$ -13.70M	$ -11.51M	$ 7.77M	$ -39.66M	$ -14.39M	$ -7.91M
Normalized Income	$ -11.10M	$ -13.43M	$ -11.22M	$ -35.49M	$ -17.19M	$ -7.62M
Interest Expense	$ 42.25K	$ 28.40K	$ 143.00	$ 18.57M	$ 6.36M	$ 0.00
EBIT	$ -13.65M	$ -11.48M	$ 7.77M	$ -21.09M	$ -8.03M	$ -7.91M
EBITDA	$ -13.65M	$ -11.47M	$ 7.78M	$ -21.07M	$ -8.01M	$ -7.90M

Currency in USD

Arno Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing